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Background: Embolic events are a major cause of morbidity and mortality in patients with infective endocarditis.
We analyzed the database of the prospective cohort study SEI in order to identify factors associated with the
occurrence of embolic events and to develop a scoring system for the assessment of the risk of embolism.
Methods: We retrospectively analyzed 1456 episodes of infective endocarditis from the multicenter study SEI.
Predictors of embolism were identified. Risk factors identified at multivariate analysis as predictive of embolism in
left-sided endocarditis, were used for the development of a risk score: 1 point was assigned to each risk factor (total
risk score range: minimum 0 points; maximum 2 points). Three categories were defined by the score: low (0 points),
intermediate (1 point), or high risk (2 points); the probability of embolic events per risk category was calculated for
each day on treatment (day 0 through day 30).
Results: There were 499 episodes of infective endocarditis (34%) that were complicated by≥ 1 embolic event. Most
embolic events occurred early in the clinical course (first week of therapy: 15.5 episodes per 1000 patient days;
second week: 3.7 episodes per 1000 patient days). In the total cohort, the factors associated with the occurrence of
embolism at multivariate analysis were prosthetic valve localization (odds ratio, 1.84), right-sided endocarditis (odds
ratio, 3.93), Staphylococcus aureus etiology (odds ratio, 2.23) and vegetation size ≥ 13 mm (odds ratio, 1.86). In left-
sided endocarditis, Staphylococcus aureus etiology (odds ratio, 2.1) and vegetation size ≥ 13 mm (odds ratio, 2.1)
were independently associated with embolic events; the 30-day cumulative incidence of embolism varied with risk
score category (low risk, 12%; intermediate risk, 25%; high risk, 38%; p < 0.001).
Conclusions: Staphylococcus aureus etiology and vegetation size are associated with an increased risk of embolism.
In left-sided endocarditis, a simple scoring system, which combines etiology and vegetation size with time on
antimicrobials, might contribute to a better assessment of the risk of embolism, and to a more individualized
analysis of indications and contraindications for early surgery.
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Embolic events are common complications of infective
endocarditis (IE) and are of prognostic importance [1-3].
Neurologic complications, mostly caused by embolic
events, are frequent causes of intensive care unit admis-
sion, and embolism is a strong predictor of death for pa-
tients who have IE [4-8].
Small, clinically inapparent emboli probably occur
in most patients who have IE, as demonstrated with
positron-emission tomography and magnetic resonance
imaging; silent cerebrovascular complications (including
ischemia and microhemorrhage) may occur in up to 81%
of patients [9-11]. Symptomatic embolism may occur in
13% to 46% of patients [6,12,13]. Many symptomatic em-
boli involve the central nervous system; clinical evidence
of cerebrovascular embolic events is present in 12% to
40% of patients who have IE; the incidence may be higher
in patients who are treated in referral centers, critically ill,
or admitted to an intensive care unit [5,6,14].
Assessment of the embolic risk in individual patients
is difficult, this having a major impact on clinical deci-
sions regarding the indications for diagnostic proce-
dures, antiaggregant and anticoagulant therapy and the
timing of cardiac valve surgery [2,3,12,15-20]. Prevention
of embolism is an established indication for surgery; in
the Euro Heart Survey, vegetation size and previous em-
bolism were reported as factors contributing to the
surgical decision in, respectively, 48% and 18% of the pa-
tients who had surgery; in the French series recently
published by Hubert et al. the presence of large vegeta-
tions (with or without previous embolism) was reported
as an indication for surgery in 36% of the 493 patients
who underwent surgery [3,21,22].
Most previous studies about the embolic complica-
tions of IE have been retrospective, with selection bias
and limited numbers of patients. In addition, the epi-
demiology and standard of care of IE have clearly
evolved over the years, and less recent observations may
no more adequately represent the contemporary clinical
profile of the disease [8,12,23-26]. The present study was
based on data from a large prospective observational co-
hort; the retrospective analysis of the database had two
main objectives: (1) to identify factors associated with
the occurrence of embolic events and (2) to design a
scoring system for the assessment of the risk of embolic
complications.
Methods
Patients
The Italian Study on Endocarditis (Studio Endocarditi
Italiano - SEI) working group was established in October
2003 in order to promote research on IE in Italy. Within
this group, a prospective, observational, multicenter, open
cohort study was designed. All consecutive episodes of IEdiagnosed from January 2004 through December 2011 at
25 secondary and tertiary care institutions were included
in the study. The diagnosis of IE was defined as possible
or definite, in accordance with the modified Duke criteria
[27]. Adult and pediatric patients were identified prospect-
ively using institution-specific procedures, so as to ensure
the consecutive enrollment of all the patients with IE
observed at each participating institution. Echocardiog-
raphy, diagnosis of embolic complications and treatment,
were in accordance with current clinical practice (the
study did not prescribe a standard diagnostic and thera-
peutic approach).
At the time of clinical observation of each patient,
clinical data were recorded in a form that was designed
for the study and registered in an electronic data entry
system. The SEI database was maintained at the Infec-
tious Diseases Department, Bergamo Hospital; the study
was approved by the ethics committee “Comitato di
Bioetica dell'Azienda Ospedali Riuniti di Bergamo”, and
patients consented to enrollment in the SEI cohort as
required by local guidelines and procedures. Details on
the SEI study have been previously published [28].
Here we present the results of a retrospective analysis
of the SEI database, aimed at investigating factors associ-
ated with the occurrence of embolic events; all the epi-
sodes of possible and definite IE were included.
Clinical data
Available information included demographic data, pre-
disposing conditions, anatomic site of disease, micro-
biology, echocardiographic findings (presence, number,
location and maximal length of vegetations), antimicro-
bial and surgical treatment, complications (heart failure,
embolic events, intracardiac abscess, persistent positive
blood cultures and new cardiac conduction abnormal-
ities) and clinical outcome (survival and New York
Hearth Association functional class). Central nervous
system embolic events were reported as transient ische-
mic attack, ischemic stroke or hemorrhagic stroke.
Peripheral embolic events were reported with details of
anatomic site. Mycotic aneurysms, meningitis, encephal-
opathy, cerebral abscesses, arthritis, spondylodiscitis and
cutaneous complications were excluded.
Infective endocarditis was classified as left-sided IE
(LS-IE), left-sided native valve IE (LS-NVE), left-sided
prosthetic valve IE (LS-PVE), right-sided IE (RS-IE) or
IE associated with a cardiac implantable electronic de-
vice (CIED-IE).
Statistical analysis
Data analysis was performed with statistical software
(Stata 13, StataCorp LP, College Station, TX). Compari-
sons were done using χ2 test (chi-square test) for propor-
tions and Mann–Whitney test for ordered or continuous
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was performed to determine the optimal vegetation size
cut-off for the prediction of embolism.
Cumulative incidence analysis was performed from the
date of starting treatment to the date of embolism (un-
censored) or discharge from the hospital (censored).
Cardiac surgery was treated as a competing event. Uni-
variate and multivariate analyses were performed with
logistic regression. Variables that were statistically sig-
nificant in univariate analysis, variables that were clinic-
ally meaningful and possible confounders, were selected
for prognostic assessment. For LS-IE, a weight was
assigned to each factor that was associated with embol-
ism, in order to build a risk score. The Kaplan‐Meier
method was used to estimate univariate cumulative inci-
dence of embolism according to the risk score. All testsTable 1 Demographic and clinical characteristics of the cohor
Characteristics All episodes LS-N
Number of IE episodes 1456 (100) 967
Age (y) 65 (50 to 64) 64 (4
Male 1018 (70) 688
Comorbidity and predisposing conditions
Native valve disease 372 (26) 299
Diabetes mellitus 268 (18) 164
Chronic liver disease 262 (18) 169
Cancer 175 (12) 131
Chronic intravenous access 154 (11) 102
Current intravenous drug abuse 131 (9) 81 (8
Previous IE 118 (8) 48 (5
Congenital heart disease 112 (8) 85 (9
Immunosuppressive therapy 86 (6) 70 (7
HIV infection 52 (4) 36 (4
Hemodialysis 29 (2) 21 (2
Microbiology
Staphylococcus aureus 283 (19) 181
Viridans group streptococci 217 (15) 172
Enterococcus species 182 (13) 117
Coagulase-negative staphylococci 147 (10) 74 (8
Streptococcus bovis 142 (10) 105
Other streptococci 59 (4) 46 (5
Other microorganisms 61 (4) 36 (4
Polymicrobial 51 (4) 34 (4
Fungi 20 (1) 12 (1
HACEK 3 (0.2) 0 (0)
Microbiology negative 291 (20) 190
*Data reported as number, median (interquartile range), or number (% patients).
Abbreviations: CIED-IE infective endocarditis associated with a cardiac implantable elec
Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae, HIV human immunod
prosthetic valve endocarditis, RS-IE right-sided infective endocarditis.were 2-sided, and statistical significance was defined by
p ≤ 0.05. The probability of the occurrence of embolic
events for each risk category was calculated for each day
on treatment (from day 1 through day 30).
Results
Clinical characteristics of patients and embolic events
During the study period, 1456 IE episodes were observed
at the participating institutions (1297 definite and 159
possible episodes); 10 episodes (0.7%) involved pediatric
patients (age <18 y); basic demographic and medical
data are summarized in Table 1.
Embolization occurred in 499 IE episodes (34.3%),
with more than one embolic event in 135 episodes
(9.3%), and a cumulative number of 700 embolic events
(Table 2). In 121/499 IE episodes (24.2%) the first embolict*
VE LS-PVE RS-IE CIED-IE
(66.4) 339 (23.3) 89 (6.1) 61 (4.2)
8 to 74) 70 (61 to 76) 48 (35 to 67) 67 (55 to 77)
(71) 221 (65) 61 (69) 48 (79)
(31) 60 (18) 7 (8) 6 (10)
(17) 79 (23) 10 (11) 15 (25)
(18) 49 (15) 38 (43) 6 (10)
(14) 28 (8) 10 (11) 6 (10)
(11) 34 (10) 11 (12) 7 (12)
) 14 (4) 34 (38) 2 (3)
) 59 (17) 7 (8) 4 (7)
) 16 (5) 6 (7) 5 (8)
) 11 (3) 2 (2) 3 (5)
) 4 (1) 10 (11) 2 (3)
) 4 (1) 2 (2) 2 (3)
(19) 53 (16) 35 (39) 14 (23)
(18) 29 (9) 8 (9) 8 (13)
(12) 53 (16) 8 (9) 4 (7)
) 55 (16) 4 (5) 14 (23)
(11) 29 (9) 7 (8) 1 (2)
) 7 (2) 3 (3) 3 (5)
) 20 (6) 2 (2) 3 (5)
) 10 (3) 4 (5) 3 (5)
) 8 (2) 0 (0) 0 (0)
2 (0.6) 1 (1) 0 (0)
(20) 73 (22) 17 (19) 11 (18)
tronic device, HACEK Haemophilus species, Actinobacillus actinomycetemcomitans,
eficiency virus, LS-NVE left-sided native valve endocarditis, LS-PVE left-sided
Table 2 Type and anatomic site of embolic events*
Characteristics All IE episodes LS-NVE LS-PVE RS-IE CIED-IE
Number of IE episodes 1456 967 339 89 61
Embolic events 700 436 166 74 24
CNS emboli 249 (36) 174 (40) 68 (41) 3 (4) 4 (17)
Ischemic stroke 176 (25) 126 (29) 45 (27) 2 (3) 3 (13)
Transient ischemic attack 42 (6) 26 (6) 14 (8) 1 (1) 1 (4)
Hemorrhagic stroke 31 (4) 22 (5) 9 (6) 0 (0) 0 (0)
Peripheral emboli 451 (64) 262 (60) 98 (59) 71 (96) 20 (83)
Pulmonary 122 (17) 26 (6) 25 (15) 57 (84) 14 (58)
Splenic 117 (17) 90 (21) 23 (14) 3 (4) 1 (4)
Limbs 95 (14) 70 (16) 15 (9) 7 (10) 3 (13)
Other 117 (17) 76 (17) 35 (21) 4 (6) 2 (8)
*Data reported as number or number (% of embolic events).
Abbreviations: CIED-IE infective endocarditis associated with a cardiac implantable electronic device, LS-NVE left-sided native valve endocarditis, LS-PVE left-sided
prosthetic valve endocarditis, RS-IE right-sided infective endocarditis.
Rizzi et al. BMC Infectious Diseases 2014, 14:230 Page 4 of 10
http://www.biomedcentral.com/1471-2334/14/230event occurred in the days preceding the diagnosis of IE
and the start of antimicrobial therapy; in 77 cases (15.4%)
on the same day of diagnosis. After the starting of anti-
microbial therapy, most embolic events occurred early
(15.5 episodes per 1000 patient days during the first week
of therapy; 3.7 episodes per 1000 patient days during the
second week of therapy) (Figure 1). In 93 IE episodes, the
disease was complicated by both CNS and peripheral em-
bolism; in 25 of these episodes CNS embolism was pre-
ceded by overt peripheral embolism.
IE episodes complicated by embolic events had a higher
in-hospital mortality (OR 1.84; 95% CI 1.36 – 2.49, p ≤
0.0001); no significant difference was observed in the rateFigure 1 Timing of embolic events. Negative values represent days befo
the beginning of antibiotic therapy; positive values represent the days afteof cardiac surgical procedures when comparing IE epi-
sodes complicated by embolism with uncomplicated IE
episodes (OR 0.98; 95% CI 0.79 – 1.23, p ns) (Additional
file 1: Appendix 1 and Additional file 2: Appendix 2).
Factors associated with embolic events
In the total cohort (including LS-IE, RS-IE, and CIED-
IE), univariate analysis showed that embolism was asso-
ciated with younger patient age, HIV infection, absence
of cancer, presence of chronic liver disease, current
intravenous drug abuse, RS-IE, larger vegetation size, S.
aureus and Enterococcus species etiology (Table 3). The
ROC curve analysis showed that a vegetation size ≥ 13 mmre the beginning of the antibiotic therapy; zero represents the day of
r the beginning of the antibiotic therapy.
Table 3 Total cohort: univariate analysis of factors associated
with embolism*
Characteristics IE episodes
with embolic
events
IE episodes
without embolic
events
p ≤ †
Number of episodes of IE 499 957
Age (y) 62 (28 to 81) 67 (31 to 84) 0.0002
Male 361 (72) 657 (69) NS
Hemodialysis 10 (2) 19 (2) NS
Diabetes mellitus 86 (17) 182 (19) NS
HIV infection 29 (6) 23 (2) 0.004
Cancer 46 (9) 129 (13) 0.03
Chronic liver disease 115 (23) 147 (15) 0.0005
Current intravenous
drug abuse
74 (15) 57 (6) 0.0001
Previous IE 38 (8) 80 (8) NS
Chronic intravenous access 59 (12) 95 (10) NS
Congenital heart disease 38 (8) 74 (8) NS
Native valve predisposition 132 (26) 270 (28) NS
Nosocomial IE 29 (6) 50 (5) NS
Health care associated IE 107 (21) 227 (24) NS
Community-acquired IE 363 (73) 680 (71) NS
Native vs prosthetic valve 385 vs 114 732 vs 225 NS
Site of IE (n = 1282)
Mitral vs aortic valve 166 vs 161 329 vs 359 NS
Bivalvular involvement
(mitral and aortic)
39 (8) 78 (8) NS
Right-sided IE 60 (12) 29 (3) 0.0001
CIED-IE 21 (4) 40 (4) NS
Vegetations (n = 710)‡
Size of all vegetations
(mm)
14 (6 to 30) 10 (4 to 26) 0.0001
≥ 10 mm 228 (79) 264 (63) 0.0001
≥ 15 mm 142 (49) 145 (35) 0.0001
≥ 20 mm 74 (26) 78 (19) 0.03
Concomitant therapy
at onset of IE
Anticoagulants 102 (20) 228 (24) NS
Antiaggregants 68 (14) 103 (11) NS
Microbiology
Staphylococcus aureus 141 (28) 142 (15) 0.0001
Viridans group
streptococci
66 (13) 151 (16) NS
Coagulase-negative
staphylococci
52 (10) 95 (10) NS
Enterococcus species 45 (9) 137 (1) 0.004
Streptococcus bovis 44 (9) 98 (10) NS
Polymicrobial 19 (4) 32 (3) NS
Other microorganisms 16 (3) 45 (6) NS
Table 3 Total cohort: univariate analysis of factors associated
with embolism* (Continued)
Other streptococci 16 (3) 43 (5) NS
Fungi/yeasts 7 (1) 13 (1) NS
HACEK 1 (0.2) 2 (0.2) NS
Microbiology negative 92 (18) 199 (21) NS
*Total cohort, N = 1456 episodes of infective endocarditis. Data reported as
number, median (range, 5th to 95th percentile), or number (%). Abbreviations:
CIED-IE infective endocarditis associated with a cardiac implantable electronic
device, HACEK Haemophilus species, Actinobacillus actinomycetemcomitans,
Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae, HIV human
immunodeficiency virus, IE infective endocarditis.
†NS, not significant (p > 0.05).
‡ IE episodes with vegetations of known size: 710 episodes (290 episodes with
embolism and 420 episodes without embolism).
Bold numbers represent statistically significant differences.
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(Figure 2). Anticoagulant therapy at the onset of the IE epi-
sode was not associated with a significant difference in the
frequency of embolic events; the same was true for antiag-
gregant therapy (Table 3). Multivariate analysis showed that
the only independent predictors of embolism were pros-
thetic valve involvement, right-side localization, vegetation
size (13 mm cut-off value) and S. aureus etiology (Table 4).
In LS-IE, univariate analysis showed that embolism
was associated with younger patient age, current intra-
venous drug abuse, larger vegetation size, S. aureus and
Enterococcus species etiology (Additional file 3: Table
S1). The ROC curve analysis showed that a vegetation
size ≥ 13 mm was significantly associated with the occur-
rence of emboli (Additional file 4: Figure S1). Multivari-
ate analysis showed that in LS-IE the only independent
predictors of embolism were vegetation size (13 mm
cut-off value; OR 2.1; 95% CI 1.5 – 2.8, p = 0.0001) and
S. aureus etiology (OR 2.1; 95% CI 1.5 – 3.1, p = 0.0001)
There were no significant differences in the frequency ofFigure 2 Total cohort: size of vegetation. Receiver operating
characteristic analysis for the prediction of embolic events, based on
vegetation size.
Table 4 Total cohort: multivariate analysis of factors
associated with embolism*
Odds ratio 95% CI p ≤ †
Age 1.0 1.0 – 1.0 NS
HIV infection 0.8 0.3 – 2.0 NS
Cancer 1.10 0.7 – 1.9 NS
Chronic liver disease 1.4 0.9 – 2.2 NS
Mitral vs aortic valve 1.0 0.7 – 1.3 NS
Prosthetic vs native valve 1.8 1.2 – 2.9 0.011
Righ-sided IE 3.9 2.0 – 7.7 <0.0001
Size of vegetation ≥ 13 mm 1.9 1.3 – 2.6 <0.0001
Staphylococcus aureus 2.2 1.5 – 3.4 <0.0001
Coagulase-negative staphylococci 1.6 1.0 – 2.6 NS
Enterococcus spp. 0.8 0.4 – 1.4 NS
Anticoagulant therapy 0.8 0.5 – 1.3 NS
*N = 1456 IE episodes. Abbreviation: HIV human immunodeficiency virus.
†NS, not significant (p > 0.05).
Bold numbers represent statistically significant differences.
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native and prosthetic valves. (Additional file 5: Table S2).
Risk score
The two risk factors for LS-IE embolism that were iden-
tified with multivariate analysis (vegetation size ≥ 13 mm
and Staphylococcus aureus etiology) were combined for
designing the risk score. Because there was no marked0.
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Figure 3 Left-sided IE: Kaplan-Meier plots of failure rates (embolic ev
at risk at any given time. Numbers in parentheses: number of embolic evendifference in the odds ratios of the 2 prognostic vari-
ables, 1 point was assigned for the presence of each fac-
tor (total risk score range: minimum 0 points; maximum
2 points), this resulting in a three-tiered score:
 low risk category (no poor prognostic factor:
etiology other than S. aureus, and vegetations size
<13 mm);
 intermediate risk category (1 poor prognostic factor:
S. aureus etiology or vegetations size ≥ 13 mm);
 high risk category (2 poor prognostic factors:
S. aureus etiology and vegetations size ≥ 13 mm).
 The 30-day cumulative incidence of embolism varied
significantly across the different risk categories:
11.8% (95% CI 7.2 – 19.2) in the low risk category,
24.5% (95% CI 20.3 – 37.0) in the intermediate risk
category, 37.7 (95% CI 22.1 – 64.9) in the high risk
category. Kaplan-Meier plots showed that the 3
risk categories differed significantly from each other
by log-rank test and test for trend (p ≤ 0.001)
(Figure 3, Table 5).
Discussion
Embolism is a common complication of infective endo-
carditis. The cumulative incidence of clinically overt em-
bolic events in our series (34.3%) is within the range
observed in most published series, notwithstanding dif-
ferences in definitions and enrollment criteria between17(5) 10(0)
150(8) 118(6)
176(5) 137(0)
20 30
from starting of therapy
Intermediate risk (score=1)
ents) for different risk categories. Bold numbers: number of patients
ts that occurred in each time interval.
Table 5 Left-sided IE: 30-day probability (%) of embolic
events per risk category
Time from start of therapy (d) Low (0) Intermediate (1) High (2)
0 11.78 24.54 37.73
1 7.90 20.82 34.79
2 6.61 18.95 25.97
3 4.88 16.13 25.97
4 4.01 14.70 25.97
5 4.01 12.78 25.97
6 3.14 11.34 25.97
7 2.71 8.95 22.81
15 0.48 5.02 3.46
30 0.00 0.00 0.00
Note: numbers represent the probability (%) of embolism at the end of a
given time interval. Time 0 values include embolic events occurred on the first
calendar day of therapy; day 1 values represent the risk at the end of the first
calendar day of therapy.
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dence of embolization observed in our study in LS-NVE
(31.4%), LS-PVE (33.6%), RS-IE (67%), CIED-IE (34.4%)
is similar to what has been reported from most contem-
porary studies: a high incidence of embolic events in
RS-IE, and an incidence in the range 20-33% for CIED-
associated IE; it has to be noted that in our study, in
contrast with other published series, we did not observe
significant differences in the frequency of embolic events
between mitral and aortic valve localization, and be-
tween LS-NVE and LS-PVE [8,15].
It is well known that embolic episodes occur early in
the course of the disease, often before the diagnosis of
IE is established and antimicrobial therapy is started; our
findings confirm this, with a large part of the embolic
events (39.6%) occurring in the days preceding the diag-
nosis or on the day of diagnosis [3,8,15]. The present
study confirms that the risk of embolism decreases
markedly after the first week of antimicrobial therapy;
this seems to support previous recommendations against
stroke prevention as the only indication for valvular sur-
gery after 1 week of therapy [15].
An embolic event may predict the risk of further
embolic events and neurologic complications, and this
may have an effect on decision making [3,14]. In our
series, central nervous system embolism was preceded
by symptomatic peripheral embolism in just 25 patients,
this apparently limiting the utility of peripheral embol-
ism as a predictor for CNS embolic complications.
These 25 patients might point to a missed opportunity
for surgical prevention of embolism, but it has to be
noted that in the SEI study data regarding the possible
presence of major contraindications for surgery were not
systematically collected.Many papers have reported on the characteristics of
vegetations which are predictive of the risk of embolism
[1,3,7,12,25,26,31]; lacking a standardized echocardio-
graphic study of our patients, the analysis was restricted
to the size of the vegetations, which is a major determin-
ant of the embolic risk, as underlined by two meta-
analyses [32,33]. The cut-off value of 13 mm derived by
our cumulative analysis (and confirmed by an analysis
restricted to the LS-IE episodes) is within the range
commonly discussed in the literature (10 mm or 15 mm
for LS-IE, and 20 mm for RS-IE) [3,7,12,25,26,31].
S. aureus has been associated with an increased risk of
embolic events; our data clearly confirm this, with an
OR for S. aureus versus all other microbial agents of 2.2
[3,7,8,15,34]. A few papers have also reported on a
higher incidence of embolic complications in Streptococ-
cus bovis IE: our analysis of 142 S. bovis IE episodes did
not confirm these findings; it has to be noted that in the
report by Pergola et al. (40 S. bovis episodes), a signifi-
cant difference was observed when comparing S. bovis
with other streptococci, but not when comparing S.
bovis with other pathogens; and Tripodi et al. found a
significant difference when comparing S. bovis IE (30 ep-
isodes) with IE due to other etiological agents (p = 0.002
at univariate analysis); however, patients with S. bovis IE
were older and had a higher rate of bivalvular involve-
ment [7,35,36]. High rates of embolic events have been
described in fungal endocarditis (43% in 21 cases of
PVE-IE reported by Boland); in our series (20 fungal epi-
sodes) we did not observe a significant difference when
comparing fungal IE episodes with episodes due to other
pathogens [37-39].
In our series age, sex and a number of predisposing
and comorbidity conditions were not found to be associ-
ated with the occurrence of embolic events, and were
not included in the score; this is in contrast with what
has recently been proposed by Hubert et al., which in-
cluded in their risk calculator not only vegetation size
(10 mm cut-off ) and S. aureus etiology, but also age, dia-
betes, previous embolism and atrial fibrillation [3].
Despite the large sample size in the present study,
only 2 factors were significantly associated with the oc-
currence of embolic events in LS-IE: vegetation size ≥
13 mm and S. aureus etiology. These variables were in-
corporated into a 3-tiered risk score; the 3 categories of
the scoring system were associated with clinically rele-
vant differences in the risk of developing embolic events.
Combining the risk category with the number of days on
antimicrobials could be used to assess the probability of
embolism (as shown in Table 5), in order to compare
the embolic risk with the risks associated with surgery,
making it possible to individualize a patient’s evaluation,
especially during the crucial first days of the clinical
course. However, differences in patient populations,
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dictive value of the score. Therefore, the clinical use of
the scoring system will be possible only following suc-
cessful external validation.
Our study has inherent limitations: firstly, the partici-
pant centers were secondary and tertiary care units,
where a major interest in the field of IE had developed;
yet, patients with IE are admitted all over the country to
Infectious Diseases, Internal Medicine, Cardiology, Car-
diac Surgery wards and to intensive care units, and a re-
ferral bias has to be taken in account; in fact, our data
do not represent the wide range of clinical conditions
and patterns of treatment which are observed across
Italy, and there is clearly the need for large, population-
based studies, which could better describe the full
spectrum of the disease, as currently observed and treated
in our country. Secondly, echocardiographic evaluation
was left to local expertise, without a centralized stan-
dardization or supervision: this may have limited our abil-
ity to identify characteristics of the vegetations that may
be associated with the occurrence of embolic events. Fi-
nally, embolization was diagnosed at the different institu-
tions in accordance with current clinical practice, and
therefore differences in the diagnostic approach may have
reduced the discriminatory power of our analysis.
Conclusions
Embolism occurs early in the course of IE; the steep de-
cline of the risk of embolization immediately after anti-
biotics initiation allows only a narrow time window for
the surgical prophylaxis of embolic complications. In
this challenging clinical context, the simple score system
described in the present study, if externally validated,
might contribute to a timely and individualized assess-
ment of the embolic risk.
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